Literature DB >> 18840494

Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1).

Ruth Harvey1, Jun X Wheeler, Chantal L Wallis, James S Robertson, Othmar G Engelhardt.   

Abstract

The assessment of potential candidate influenza vaccine viruses includes a number of factors. Growth properties of the virus and yield of antigen, specifically the haemagglutinin (HA), are of key importance. The recently developed H5N1 candidate vaccine virus NIBRG-14 (with HA and NA genes derived from the clade 1 virus A/Viet Nam/1194/2004 in an A/Puerto Rico/8/34 background) has been suggested to yield low amounts of antigen. While investigating the antigen yield of H5N1 vaccine viruses, we found that accurate quantitation of the HA content of some H5N1 viruses was difficult due to the migration characteristics of the proteins on SDS-PAGE gels. The HA1 and HA2 bands co-migrated with nucleoprotein (NP) and matrix protein (M1) respectively, preventing accurate analysis. We have developed an accurate way of quantitating HA from these H5N1 viruses by introducing a deglycosylation step to the standard protocol. Using this method, we showed reproducibly that the low yield of NIBRG-14 is, at least in part, due to a lower than usual content of HA in virus preparations. This was also found to be the case for the parent wild type A/Viet Nam/1194/2004 virus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840494     DOI: 10.1016/j.vaccine.2008.09.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.

Authors:  Caroline Gravel; Changgui Li; Junzhi Wang; Anwar M Hashem; Bozena Jaentschke; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  J Vis Exp       Date:  2011-04-04       Impact factor: 1.355

2.  Intradermal delivery of a fractional dose of influenza H7N9 split vaccine elicits protective immunity in mice and rats.

Authors:  Shanshan Zhou; Tianyu Ren; Hongjing Gu; Cheng Wang; Min Li; Zhongpeng Zhao; Li Xing; Liangyan Zhang; Yi Sun; Penghui Yang; Xiliang Wang
Journal:  Hum Vaccin Immunother       Date:  2018-02-12       Impact factor: 3.452

3.  Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules.

Authors:  Ruth Harvey; Kate A Guilfoyle; Sarah Roseby; James S Robertson; Othmar G Engelhardt
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

4.  Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt.

Authors:  Mokhtar Rizk Gomaa; Ahmed Ali Khalil; Ahmed Kandeil; Jamal S M Sabir; Ahmed Kayed; Yassmin Moatasim; Marwa F El Saied; Mounir M El-Safty; Ghazi Kayali; Mohamed A Ali
Journal:  Poult Sci       Date:  2019-12-01       Impact factor: 3.352

5.  Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.

Authors:  Changgui Li; Kangwei Xu; Anwar Hashem; Ming Shao; Shuzhen Liu; Yong Zou; Qiang Gao; Yongchao Zhang; Liyong Yuan; Miao Xu; Xuguang Li; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Impact of prior seasonal H3N2 influenza vaccination or infection on protection and transmission of emerging variants of influenza A(H3N2)v virus in ferrets.

Authors:  Katherine V Houser; Melissa B Pearce; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

7.  Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines.

Authors:  Xiangjie Sun; Weiping Cao; Claudia Pappas; Feng Liu; Jacqueline M Katz; Terrence M Tumpey
Journal:  Virology       Date:  2014-07-30       Impact factor: 3.616

8.  Developing vaccines to combat pandemic influenza.

Authors:  James S Robertson; Othmar G Engelhardt
Journal:  Viruses       Date:  2010-02-02       Impact factor: 5.818

9.  Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].

Authors:  Rachel E Johnson; Michelle Hamill; Ruth Harvey; Carolyn Nicolson; James S Robertson; Othmar G Engelhardt
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

10.  Recombinant influenza vaccines.

Authors:  E S Sedova; D N Shcherbinin; A I Migunov; Iu A Smirnov; D Iu Logunov; M M Shmarov; L M Tsybalova; B S Naroditskiĭ; O I Kiselev; A L Gintsburg
Journal:  Acta Naturae       Date:  2012-10       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.